252 related articles for article (PubMed ID: 16883935)
1. [Pathomorphology of membranes appearing in proliferative vitreoretinopathies].
Laudańska-Olszewska I; Omulecki W; Dziegielewski K; Pikulski Z; Omulecka A
Klin Oczna; 2006; 108(1-3):28-31. PubMed ID: 16883935
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes.
Tsanou E; Ioachim E; Stefaniotou M; Gorezis S; Charalabopoulos K; Bagli H; Peschos D; Psilas K; Agnantis NJ
Int J Clin Pract; 2005 Oct; 59(10):1157-61. PubMed ID: 16178982
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis and cell proliferation in proliferative retinal disorders: PCNA, Ki-67, caspase-3, and PARP expression.
Zhang X; Barile G; Chang S; Hays A; Pachydaki S; Schiff W; Sparrow J
Curr Eye Res; 2005 May; 30(5):395-403. PubMed ID: 16020270
[TBL] [Abstract][Full Text] [Related]
4. Diverse NF-kappaB expression in epiretinal membranes after human diabetic retinopathy and proliferative vitreoretinopathy.
Harada C; Harada T; Mitamura Y; Quah HM; Ohtsuka K; Kotake S; Ohno S; Wada K; Takeuchi S; Tanaka K
Mol Vis; 2004 Jan; 10():31-6. PubMed ID: 14737065
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
6. Indicators of oxidative tissue damage and inflammatory activity in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
Augustin AJ; Spitznas M; Koch F; Grus F; Böker T
Ger J Ophthalmol; 1995 Jan; 4(1):47-51. PubMed ID: 7728110
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells.
Casaroli-Marano RP; Pagan R; Vilaró S
Invest Ophthalmol Vis Sci; 1999 Aug; 40(9):2062-72. PubMed ID: 10440262
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical study of extracellular matrix components in epiretinal membranes of vitreoproliferative retinopathy and proliferative diabetic retinopathy.
Ioachim E; Stefaniotou M; Gorezis S; Tsanou E; Psilas K; Agnantis NJ
Eur J Ophthalmol; 2005; 15(3):384-91. PubMed ID: 15945009
[TBL] [Abstract][Full Text] [Related]
9. Localisation of opticin in human proliferative retinal disease.
Pattwell DM; Sheridan CM; Le Goff M; Bishop PN; Hiscott P
Exp Eye Res; 2010 Mar; 90(3):461-4. PubMed ID: 20036236
[TBL] [Abstract][Full Text] [Related]
10. Pathological changes in the vitreoretinal junction 1: epiretinal membrane formation.
Snead DR; James S; Snead MP
Eye (Lond); 2008 Oct; 22(10):1310-7. PubMed ID: 18344963
[TBL] [Abstract][Full Text] [Related]
11. Active scatter factor (HGF/SF) in proliferative vitreoretinal disease.
Briggs MC; Grierson I; Hiscott P; Hunt JA
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3085-94. PubMed ID: 10967068
[TBL] [Abstract][Full Text] [Related]
12. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
Abu El-Asrar AM; Struyf S; Kangave D; Geboes K; Van Damme J
Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy.
Bochaton-Piallat ML; Kapetanios AD; Donati G; Redard M; Gabbiani G; Pournaras CJ
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2336-42. PubMed ID: 10892881
[TBL] [Abstract][Full Text] [Related]
14. Effect of Robo1 on retinal pigment epithelial cells and experimental proliferative vitreoretinopathy.
Huang L; Xu Y; Yu W; Li Y; Chu L; Dong J; Li X
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3193-204. PubMed ID: 20071679
[TBL] [Abstract][Full Text] [Related]
15. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy.
Roldán-Pallarés M; Rollín R; Mediero A; Martínez-Montero JC; Fernández-Cruz A; Bravo-Llata C; Fernández-Durango R
Mol Vis; 2005 Jul; 11():461-71. PubMed ID: 16030497
[TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemical study on vitrectomy specimens of proliferative retinal diseases].
Cao J; Wu L; Zhang H
Zhonghua Yan Ke Za Zhi; 1997 Jul; 33(4):264-7. PubMed ID: 10451957
[TBL] [Abstract][Full Text] [Related]
17. Atrial natriuretic peptide in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy.
Rollin R; Mediero A; Martínez-Montero JC; Roldán-Pallarés M; Suárez-Leoz M; Vidal-Fernández P; Cortés-Valdés C; Fernández-Cruz A; Fernández-Durango R
Mol Vis; 2004 Jul; 10():450-7. PubMed ID: 15273657
[TBL] [Abstract][Full Text] [Related]
18. Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy.
Hagedorn M; Esser P; Wiedemann P; Heimann K
Ger J Ophthalmol; 1993 Feb; 2(1):28-31. PubMed ID: 7679595
[TBL] [Abstract][Full Text] [Related]
19. Different expression of vascular endothelial growth factor and pigment epithelium-derived factor between diabetic and non-diabetic epiretinal membranes.
Nam DH; Oh J; Roh JH; Huh K
Ophthalmologica; 2009; 223(3):188-91. PubMed ID: 19182495
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy.
Lashkari K; Rahimi N; Kazlauskas A
Invest Ophthalmol Vis Sci; 1999 Jan; 40(1):149-56. PubMed ID: 9888438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
